Full Judgment Text
Text read from the judgment PDF published on the High Court's eCourts portal, through the
Indian High Court Judgments open data set (Dattam Labs,
CC BY 4.0).
The court's own copy is the authoritative text.
*
IN THE HIGH COURT OF DELHI AT NEW DELHI
%
+
Judgment delivered on: 17.01.2026
C.A.(COMM.IPD-PAT) 45/2023
HIROTSU BIO SCIENCE INC
.....Appellant
Versus
ASSISTANT CONTROLLER OF PATENTS AND
DESIGNS
.....Respondent
Advocates who appeared in this case
For the Appellant
:
For the Respondent :
Mr. Kshitij Saxena, Mr.
Vijayvargiya & Mr. Daksh
Advocates.
Saransh
Oberoi,
Ms. Manisha Agarwal & Mr. Nipun Jain,
Advocates.
CORAM:
HON'BLE MR. JUSTICE TEJAS KARIA
JUDGMENT
TEJAS KARIA, J
INTRODUCTION
1.
This is an Appeal under Section 117A of the Patents Act, 1970
(“Act”) against the order dated 29.08.2023 (“Impugned Order”) issued by
Assistant Controller of Patents and Designs (“Respondent / Controller”)
under Section 15 of the Act rejecting the grant of patent in the Patent
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
Application No. 201617022947 titled as “CANCER DETECTION METHOD
USING SENSE OF SMELL OF NEMATODE”. (“Subject Application”).
FACTUAL MATRIX
2.
The Appellant filed the National Phase Application with Claim Nos.
1-21 before the Patent Office, Delhi on 04.07.2016, based on the PCT
Application No. PCT/JP2014/083320 dated 10.12.2014.
3.
The Appellant on 31.10.2017, filed for the request for First
Examination Report. Upon receipt of the First Examination Report dated
19.08.2020 (“FER”), the Appellant filed a detailed response to the FER on
28.12.2020 (“Reply”) along with a revised set of claims.
4.
After the Reply to the FER, the Appellant received a hearing notice
dated 08.02.2023. Thereafter, the Appellant filed two requests for
adjournment of hearing and received the hearing notice on 21.03.2023
(“Hearing Notice”) containing objections stating that the claims do not
fulfil the requirements of Sections 2(1)(j), 3(i), 3(j) and sufficiency of
disclosure under Section 10(4) of the Act and fixed the hearing on
11.04.2023 (“Hearing”). During the Hearing, the Appellant advanced oral
submissions in respect of the objections raised in the Hearing Notice.
5.
The Appellant
filed
post-hearing
written
submissions
dated
26.05.2023 along with amended set of claims (“Written Submissions”).
Subsequent to the filing of the Written Submissions, the Respondent rejected
the grant of patent under the Subject Application vide the Impugned Order.
6.
The Respondent while rejecting the Subject Application in the
Impugned Order observed that the Appellant did not fulfil the requirement
under Section 3(i) of the Act.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
SUBMISSIONS ON BEHALF OF THE APPELLANT
7.
The learned Counsel for the Appellant submitted that:
7.1.
The present invention is directed to detection, i.e., identifying cancer-
specific odour responses in biological samples outside the human body. It
does not amount to diagnosis, which requires medical correlation,
interpretation, and clinical judgment. Reliance was placed upon Paragraph
Nos. [0027] and [0028] of the Complete Specification, which are reproduced
hereunder:
“[0027] The present invention relates to a method for
detecting cancer, which is characterized in breeding
nematodes in the presence of a subject-derived bio-related
substance or a processed product thereof, and then detecting
cancer, for example, using the chemotaxis of the nematodes
based on the olfaction thereof as an indicator.
Upon testing whether or not a subject has had cancer, the
present inventor has focused on, in one aspect, the
chemotaxis of the nematode C. elegans based on the olfaction
thereof to a sample derived from the subject.
A nematode, Caenorhabditis elegans (hereinafter also
abbreviated as "C. elegans"), is a popular organism, which
has been widely bred and studied as a model organism for
biological study in laboratories over the world. 2
Caenorhabditis elegans is characterized in that the breeding
thereof is easy and it has an excellent olfactory system.
[0028] Such nematodes exhibit a chemotaxis to an odorant,
such as approaching to or escaping from it. Thus, in the
present invention, using such a behavior as an indicator, the
reactions of nematodes to the smells of cancers will be
examined. The reactions of nematodes to the urine of healthy
subjects and cancer patients have been examined. As a result,
the nematodes have exhibited an avoidance behavior to the
urine of the healthy subjects, whereas they have exhibited an
attraction behavior to the urine of the cancer patients. As a
result of the examination performed on specimens, the
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
accuracy was found to be 100% (Figure 1). Moreover,
nematodes have reacted with all of gastric cancers,
colon/rectal cancers and pancreatic cancers, including early
cancers. Hence, it has been demonstrated that, as with the
behavior of cancer detection dogs, nematodes react with
cancer-specific smells, which are common in various types of
cancers.”
The Appellant in the abovementioned paragraphs points out that the
detection interpretation refers to the primary identification of the presence or
absence of cancer using nematode behavioral or neural responses
(chemotaxis or olfactory neuron activity). It does not specify cancer type; it
only signals cancer v. non-cancer.
7.2.
The core inventive feature of the present invention lies in the
detection process, which utilizes the olfactory response of nematodes to
biological samples for identifying the presence or risk of cancer in vitro. The
reference to “diagnosis” in the Complete Specification is only illustrative,
intended to provide contextual understanding for a person skilled in the art
(“PSITA”) regarding possible downstream applications of the detection
result, but does not constitute a claimed diagnostic step.
7.3.
A productive analogy can be drawn from the relationship between the
specification and the claims. The specification is like a genus and the claims
are like the species. Applying this principle, while the specification provides
a genus level narrative that includes both detection and diagnostic contexts
for technical clarity, the species actually claimed pertains exclusively to in
vitro detection. The diagnostic elements in the description exist solely for
explanatory purposes; to clarify how the detection results may be interpreted
or subsequently utilized but these are not part of the claimed process.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
7.4.
The abovementioned interpretation aligns with established patent
jurisprudence, which recognizes that the claims, not the description,
determine the scope of legal protection. Here, every independent claim,
including Claim Nos. 1 and 5, confines the method to in vitro detection or
receptor identification carried out outside the human body, without any
diagnostic or therapeutic act performed on a patient. Therefore, the
diagnostic step referred to in the Complete Specification merely illustrates a
subsequent potential use following detection, akin to how a test kit’s data
may be used by physicians for medical decision-making. It does not render
the Subject Application diagnostic in nature under Section 3(i) of the Act.
7.5.
Further, the claims define the legal monopoly granted by a patent. The
specification serves as an explanatory document, to be referred to only when
ambiguity exists in the claims. Claims must be interpreted objectively, in
their plain and ordinary meaning, through the eyes of a PSITA as of the
effective filing date and the body of the specification cannot be used to
extend or cut down the monopoly defined in the claims. This collectively
holds that it is unjust to read into a claim something beyond its clear terms,
or to import limitations or inferences from the specification unless the claim
itself is ambiguous. Reliance was placed upon the following decisions while
making the above submission:
a. F. Hoffmann-La Roche Ltd. & Anr. v. Cipla Ltd., Neutral
Citation: 2015:DHC:9674-DB
b. FH & B v. Unichem Laboratories, 1968 SCC OnLine Bom 118
c. Merck Sharp and Dohme Corporation & Anr. v. Glenmark
Pharmaceuticals, (2015) 6 SCC 807
d. Edward H. Phillips v. AWH Corp., 415 F. 3d 1303
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
7.6.
In the Subject Application, the independent claims, particularly Claim
Nos. 1 and 10 are directed to an “in vitro method for detecting cancer” using
nematodes’ olfactory behavior as an indicator. The claim language explicitly
restricts the scope to “in vitro” conditions and no step involves diagnosis,
treatment, or medical decision-making on a human or animal body. Thus,
when read plainly, the claim falls entirely outside the exclusion of Section
3(i) of the Act.
7.7.
Reliance was placed upon the decision in EMD Millipore
Corporation v. Assistant Controller of Patents and Designs, Neutral
Citation: 2025:DHC:8928 wherein the Court held that the exclusion under
Section 3(i) of the Act is not meant to create a blanket prohibition against all
inventions related to diagnosis or treatment, but only those that directly
involve medical professional judgment or physical intervention in the human
or animal body.
7.8.
The ratio laid down in EMD Millipore, (supra) squarely applies to the
present case. The Appellant’s present invention is an in vitro, non-clinical
detection process that employs nematodes’ olfactory response to biological
samples to generate a risk indication of cancer presence. The process does
not require medical expertise, does not involve any invasive step, and is
conducted entirely outside the human body in a laboratory environment.
7.9.
The Respondent failed to take into consideration the decision in
Chinese University of Hong Kong and Sequenom, Inc. v. The Assistant
Controller of Patents and Designs, 2023 SCC OnLine Mad 6372 wherein
the Court held that the assessment to be undertaken is whether the test is
inherently and per se capable of identifying the disease, disorder, or
condition for treatment of the person. The test should, in turn, be determined
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
by assuming that PSITA, including a medical doctor, examine the results.
Further, the scope of the expression “diagnostic” in Section 3(i) of the Act
should be restricted to in vivo processes.
7.10. The Respondent has failed to appreciate the fact that the Claim Nos. 1
to 4 are related to “an in vitro method of detecting cancer”; therefore, it is
clear that the method of the invention is not performed on human body but
in vitro i.e., on samples obtained from the subjects. The present claims are
related to in vitro detection methods and therefore, cannot be regarded as
diagnostic method.
7.11. The Respondent failed to acknowledge that the cancer detection
service “N-NOSE®” has been in the news and has attracted much attention
in India. “N-NOSE®” has already become a business in Japan. In fact, “NNOSE®” is commercialized in Japan and provides information whether a
customer may have cancer risk based on the chemotaxis of nematodes to the
smell of the customer’s urine, and is not a diagnosis. Therefore, responses of
nematodes merely indicate the possibility of cancer and cannot used for
diagnosing cancer.
7.12. Accordingly, the Impugned Order is liable to be set aside and the
present Appeal shall be allowed.
SUBMISSIONS ON BEHALF OF THE RESPONDENT
8.
The learned Counsel for the Respondent submitted that:
8.1.
The Appellant argued that the present claims are related to in vitro
detection methods and therefore, cannot be regarded as diagnostic method.
However, it is objected that claims of the Subject Application are a method
for detecting and characterizing cancer type in human subjects which is not
allowed under Section 3(i) of the Act.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
8.2.
Section 3(i) of the Act excludes both in vivo and in vitro methods. In
its plain reading, the provision does not qualify any of the exclusions with
the phrase “in vivo” or “in vitro”. As a general proposition of law, it is well
settled that one is not ordinarily permitted to add or delete words from the
statute. Therefore, restricting the claims to the in vitro method does not
exclude the claimed method from the objection of Section 3(i) of the Act.
Reliance was placed upon the decision in Union of India v. Hansoli Devi,
(2002) 7 SCC 273 while making the above submission.
8.3.
The Appellant further argued that the detection methods differ
significantly from diagnostic methods. Diagnostic methods require the skill
and knowledge of the physician or surgeon to analyze and interpret
symptoms, whereas in the case of detection, the result is not accompanied by
a discussion. Detection is viewed as an independent process directly
obtained by the detection method, which does not require the skill and
knowledge of a physician or surgeon. In this regard, the claimed method is
clearly a diagnostic method and it involves all the essential steps of a
diagnostic method viz.
a. the examination phase involving collection of data,
b. comparison of these data with standard values,
c. the finding of any significant deviation, i.e., a symptom, during
the comparison, and
d. the attribution of the deviation to a particular clinical picture, i.e.,
the deductive medical decision phase.
8.4.
Further, merely because the ultimate end-use of a particular claim
may be applied by biomedical or veterinary practitioners to diagnose a
disease or condition, would not automatically exclude it from patentability.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
Furthermore, the Appellant argued that the amended Claim No. 5 is directed
to a method for identifying olfactory receptors in nematodes and that this
method is for use in deciding which nematodes to use in the cancer detection
method, and thus, is not related to the diagnostic method. However, as
evident from Claim No. 5 itself that the said method is vital for the purpose
of determining the type of cancer as per the claimed diagnostic method i.e.,
deciding which nematodes to use in the cancer detection method and it is of
no use when seen in isolation.
8.5.
The specifications provide the context in which claims / amended
claims are interpreted. Complete Specification of the Subject Application
admit that the process sought to be patented is a diagnostics process. Further,
the Complete Specification of the Subject Application provides that the
process sought to be patented is not limited to just screening process for
diagnosing cancer before it happens; but it also a general diagnosing method
for cancer. It is clear that the Appellant’s averment to the effect that
specifications can expand or limit the scope of claims is not applicable here
because here, there is a contrast between the import of the specifications
versus the import of the amended claims. Assuming that the amended claims
claim only screening and that too without eliminating the need of further
tests because the claims cannot be read contrary to specifications. Reliance
was placed upon the following decisions while making the above
submission:
a. The Chinese University of Hong Kong (supra)
b. Natera Inc. and Anr. v. Assistant Controller of Patents and
Designs, Neutral Citation: 2025:DHC:8937
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
c. Sequenom Inc. & Anr. v. the Controller of Patents, Neutral
Citation: 2025:DHC:8926
8.6.
In light of the above, the Impugned Order shall be upheld and the
present Appeal is liable to be set aside.
ANALYSIS AND FINDINGS
9.
The present invention relates to the cancer detection method using the
olfactory system of nematodes. The Appellant’s Subject Application was
refused on the ground of not fulfilling the requirements under Section 3(i) of
the Act. The inventor of the present invention has found that cancer can be
detected by using the chemotaxis of nematodes based on the olfaction
thereof or the response of olfactory neuron.
10.
The analysis observed by the learned Controller under the Impugned
Order is reproduced hereunder:
“Section 3(i):
In response to para 4 regarding non-patentability under section 3(i)
in the hearing notice; the argument given by the applicant is not
persuasive and method claimed in presently amended claims 1-11 is
not allowable under section 3(i) of the Patents Act.
The applicant argues that the present claims are related to in-vitro
detection methods and therefore cannot be regarded as diagnostic
method.
However, it is objected that instant application claims a method for
detecting and characterizing cancer type in human subject which is
not allowed under section 3(i) of The Patent Act.
Regarding Section 3(i) of the Patents Act, 1970, as it stands today,
reads as follows:
“What are not inventions.The following are not inventions within the meaning of the Act,(i) any process for the medicinal, surgical, curative, prophylactic
diagnostic, therapeutic or other treatment of human beings or any
process for a similar treatment of animals to render them free of
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
disease or to increase their economic value or that of their
products.”
From the above, Section 3(i) excludes both in vivo and in vitro
methods. In its plain reading, the provision does not qualify any of
the exclusions with the phrase “in vivo” or “in vitro”. As a general
proposition of law, it is well settled that one is not ordinarily
permitted to add or delete words from the statute [Union of India v.
Hansoli Devi, (2002) 7 SCC 273 @ para 9 - Pg. 12@19-21 of
present Submissions].
Therefore, by restricting the claims to in vitro method does not
exclude the claimed method from the objection of section 3(i).
Further, applicant argues that, the detection methods differ
significantly from diagnostic methods. Diagnostic methods require
the skill and knowledge of the physician or surgeon to analyse and
interpret symptoms, whereas in the case of detection, the result is not
accompanied by a discussion. Detection is viewed as an independent
process directly obtained by the detection method, which does not
require the skill and knowledge of a physician or surgeon.
However, claimed method clearly a diagnostic method and in
involves all the essential steps of a diagnostic methods viz.
i) the examination phase involving collection of data,
ii) comparison of these data with standard values,
(iii) the finding of any significant deviation, i.e., a symptom, during
the comparison, and
(iv) the attribution of the deviation to a particular clinical picture,
i.e., the deductive medical decision phase.
Further, merely because the ultimate end-use of a particular claim
may be applied by biomedical or veterinary practitioners to
diagnose a disease or condition, would not automatically exclude it
from patentability.
Furthermore, applicant argues that amended claim 5 is directed to a
method for identifying olfactory receptors in nematodes and that this
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
method is for use in deciding which nematodes to use in the cancer
detection method, and thus is not related to the diagnostic method.
However, as evidence from the claim 5 itself that the said method is
a one of the preparatory step of claimed diagnostic method i.e.
deciding which nematodes to use in the cancer detection method and
it is of no use when seen in isolation. Further, limitations of claim 5
refers to a diagnostic method and therefore claim 5 and dependent
claims attracts the objection under section 3 (i).”
11.
Aggrieved by the Impugned Order, the learned Counsel for the
Appellant submitted that the present invention is directed to detection, that
is, identifying cancer-specific odour responses in biological samples outside
the human body and it does not amount to diagnosis, which requires medical
correlation, interpretation, and clinical judgment. The Appellant further
submitted that the detection interpretation refers to the primary identification
of the presence or absence of cancer using nematode behavioural or neural
responses (chemotaxis or olfactory neuron activity). It does not specify
cancer type; it only signals cancer v. non-cancer. There are 11 claims with 3
independent claims in the Written Submissions. The independent claims are
reproduced hereunder:
“WE CLAIM:
1. An in vitro method for detecting cancer, characterized by
detecting cancer using, as an indicator, the reaction of nematodes to
the smell of a subject-derived bio-related substance or a processed
product thereof,
wherein when the nematodes show a positive response to the smell of
the subject-derived bio-related substance or a processed product
thereof, the response result serves as the indicator to make a
determination that the subject has cancer or has cancer risk, and
wherein the bio-related substance or a processed product thereof is
a body fluid, cells, tissues, a culture of the cells or tissues, or a
preservative solution of the cells or tissues.
*****
*****
*****
5. A method for identifying an olfactory receptor in nematodes,
characterized by using mutant nematodes modified with at least one
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
selected from the group consisting of deletion of olfactory receptors,
inhibition of expression or function of olfactory receptors, and high
expression or high-functionalization of olfactory receptors; and a
body fluid, cells, tissues, a culture of the cells or tissues, or a
preservative solution of the cells or tissues of cancer patients; and
identifying an olfactory receptor by testing responses of the mutant
nematodes to the body fluid, cells, tissues, the culture of the cells or
tissues, or the preservative solution of the cells or tissues.
*****
*****
*****
10. An in vitro method for identifying cancer types, characterized by
identifying cancer types using, as an indicator, the reaction of
nematodes to the smell of a subject-derived bio-related substance or
a processed product thereof, the method comprising the following
steps:
(a) detecting cancer by the method as claimed in any one of claims 1
to 4;
(b) testing the reaction to the smell of a sample, which has been
detected to have cancer in the step(a), by using modified nematodes,
which have been prepared by modifying a receptor identified by
testing the reaction to a smell in nematodes engineered to inhibit the
expression of a gene encoding an olfactory receptor; and
(c) when the reaction to the smell is different between the modified
nematodes and the nematodes used in the step (a), the reaction
result serves as an indicator to make a determination that the cancer
types corresponding to the identified receptor are cancer types as a
target of the identification.”
12.
As per the learned Counsel for the Appellant, the core inventive
feature of the present invention lies in the detection process, which utilizes
the olfactory response of nematodes to biological samples for identifying the
presence / risk of cancer in vitro. The specification is like a genus which
serves as an enabling disclosure, ensuring that PSITA can practice the
invention without undue experimentation, while the claims are like species.
It is case of the Appellant that the said interpretation aligns with established
patent jurisprudence recognizing claims, not the description, that determine
the scope of legal protection.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
13.
Therefore, the Appellant submitted that in the Subject Application, the
independent claims (particularly Claim Nos. 1 and 10) are directed to “an in
vitro method for detecting cancer” using nematodes’ olfactory behavior as
an indicator. In other words, the claim language explicitly restricts the scope
to “in vitro” condition. The Appellant also relied on Paragraph Nos. 51 and
52 of The Chinese University of Hong Kong (supra) and argued that the
assessment to be undertaken is whether the test is inherently and per se
capable of identifying the disease, disorder or condition for treatment of the
person. The relevant paragraphs are reproduced hereunder:
“51. Thus, the claimed invention is per se incapable of identifying
the existence or otherwise of a disease, disorder or condition and
further testing would be required for such purpose. In effect, it
provides an indicator, foetal fraction, which is relevant for further
testing to arrive at a diagnosis. In my analysis of the word
“diagnostic” in Section 3(i), I concluded that the scope should not
be unduly curtailed by limiting it to in vivo or definitive diagnosis. I
also concluded that its scope should not be unduly expanded by
implying the words “relating to” diagnosis. In my view,
determination of foetal fraction is related to diagnosis but is not
“diagnostic”. The contention of learned SPC that the test may be
used for sex determination under the PNDT Act is also not relevant
from a patent application evaluation perspective because said
statute prohibits sex selection and prescribes penalties in respect
thereof. Therefore, the impugned order calls for interference. In the
FER and hearing notice, objections were raised on grounds of lack
of novelty and unity of invention and obviousness in respect of
original claims 1-33. After all those claims were deleted, as regards
amended claims 1-12, the only objection was on the basis of Section
3(i). Since such objection stands rejected as untenable, the
application shall proceed to grant.
52. Before drawing the curtain, I am, nonetheless, constrained to
make a few observations. My conclusions in this matter are founded
on an interpretation of Section 3(i) by examining the text thereof in
context. I notice that the Patent Office has granted patents to in vitro
processes and there is inconsistency. I also recognize that several
technological advancements have been made in diagnosis,
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
especially by using genomic tools. With a view to incentivize
inventors in these cutting-edge areas, albeit without compromising
on the public policy exclusion from patent eligibility of methods of
diagnosis and treatment adopted by medical doctors, there is a case
to consider options such as restricting the scope of the expression
'diagnostic' in Section 3(i) to in vivo processes and counter
balancing by providing for compulsory licensing. Since this is
squarely within the province of law makers, I stop with urging such
reconsideration.”
14.
Per contra, the Respondent while relying on the Paragraph No. 30 of
the decision in The Chinese University of Hong Kong (supra) submitted
that that Section 3(i) of the Act, in contrast to Article 52(4) of the EPC, does
not contain the expression “practised on the human or animal body”,
therefore, reinforces the conclusion that the expression “diagnostic” under
the said Section 3(i) of the Act extends both to in vitro and in vivo diagnosis.
The relevant paragraph is reproduced hereunder:
“30. The EBoA noticed the language of Article 52(4) of the EPC
and, in particular, the expression "diagnostic methods practised on
the human or animal body", and, on that basis, in paragraph 6.1 of
the opinion, concluded that the text of the provision itself gives an
indication favouring a narrow interpretation. The fact that Section
3(i), in contrast to Article 52(4) of the EPC, does not contain the
expression “practised on the human or animal body", reinforces the
conclusion that the expression 'diagnostic' in Section 3(i) extends
both to in vitro and in vivo diagnosis.”
15.
The Respondent also relied upon the decision in Natera Inc. and Anr.
(supra) which describes that the manner in which diagnosis is performed
under the “diagnostic process” is important to determine the patentability.
The relevant paragraphs are reproduced hereunder:
“61. The intention behind these provisions is clearly to provide
immunity to medical practitioners, technicians, nursing attendants
and other persons, who may be coming in contact with human
beings or animals requiring diagnosis or treatment. Thus, any
process used by such persons using their own skill and knowledge
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
for diagnosis or medicinal, surgical, curative, prophylactic,
therapeutic treatment would be excluded from patentability. For
example, if the medical practitioner finds a new process of
diagnosing diabetes by looking at a patient’s skin, such a process
would not be patentable as it would be permissible for all
practitioners to use that process. However, if a tool is developed for
diagnosing diabetes by merely placing the same on the skin of a
human being, such a tool or product can be patented.
*****
*****
****
79…. (e) ‘Diagnostic process’ - The manner in which diagnosis is
performed would not be patentable, for example, the manner of
checking blood pressure using different tools, the manner of doing
a swab test, the process of checking glucose levels, etc., would not
be patentable. However, diagnostic products, diagnostic tools,
diagnostic devices are patentable so long as they satisfy the test of
patentability and they do not unfairly monopolize processes of
diagnosis which are to be generally used by medical practitioners,
nurses etc. It is also clear that Section 3(i) does not make any
distinction between in vivo or in vitro processes…
****
****
****
99. This Court also notes that the subject invention may have been
patented in some foreign jurisdictions, however, the statutory
prohibition in India being what it is, the mere grant in foreign
jurisdictions would not lead to grant of the patent in India.”
16.
On this, the Appellant argued that the Claim Nos. 1 to 4 of the present
invention relates to “an in vitro method of detecting cancer” and therefore, it
is clear that the method of the invention is not performed on human body but
in vitro that is on samples obtained from the subjects.
17.
Contrary to the submission of the Appellant, the Paragraph No. 79 of
Natera Inc. and Anr. (supra) clearly notes that the Section 3(i) of the Act
does not make any distinction between in vivo or in vitro processes. Both
The Chinese University of Hong Kong (supra) and Natera Inc. and Anr.
(supra) have clearly interpreted that Section 3(i) of the Act prohibits both in
vivo and in vitro processes. Therefore, Section 3(i) of the Act does not
differentiate between the in vivo and in vitro processes.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
18.
To understand the present invention, it is important to peruse the
Complete Specification of the Subject Application to determine the object
and the detail of the method claimed. According to the Complete
Specification, the problem solved by the present invention is to detect the
cancer by using the chemotaxis of nematodes based on the olfaction / the
response of olfactory neuron. The problem solved by the preset invention is
reproduced hereunder:
“MEANS TO SOLVE THE PROBLEM
[0008]
As a result of intensive studies directed towards solving the
aforementioned problem, the present inventor has found that cancer
can be detected, using the chemotaxis of nematodes based on the
olfaction thereof 5 or the response of olfactory neuron, thereby
completing the present invention.”
19.
The Complete Specification under the title “Effect of the Invention”
states that the method of the present invention under the Subject Application
also involves the collection and analysis of samples. The relevant paragraph
is reproduced hereunder:
“EFFECT OF THE INVENTION
[0013]
According to the present invention, a method for detecting cancer
using a nematode is provided. According to the method of the
present invention, cancer can be detected with high sensitivity and at
low costs. Moreover, according to the method of the present
invention, collection and analysis of samples are carried out easily,
and also, it is inexpensive. Furthermore, the method of the present
invention is able to detect early cancer. Therefore, the method of the
present invention is extremely useful for clinical tests for cancer.”
20.
Further, the Paragraph Nos. [0027] and [0028] of the Complete
Specification of the Subject Application states that the accuracy was found
100% in detection of cancer. The chemotaxis index has the values from +1
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
to -1, where the chemotaxis index has a plus value when the nematodes are
attracted to the sample, i.e., urine of the subject have cancer. On the other
hand, when the nematodes avoid the sample, the chemotaxis index has a
minus value. The method involves the repetition of the analysis to be
performed on the specimen, and the mean of the repeated chemotaxis index
value is calculated. This would increase the accuracy of the result. Under the
heading “Embodiments for carrying out the Invention”, the Complete
Specification states as reproduced hereunder:
“The reactions of nematodes to the urine of healthy subjects and
cancer patients have been examined. As a result, the nematodes have
exhibited an avoidance 20 behavior to the urine of the healthy
subjects, whereas they have exhibited an attraction behavior to the
urine of the cancer patients. As a result of the examination
performed on 30 specimens, the accuracy was found to be 100%
(Figure 1).”
21.
Further, Paragraph No. [0030] of the Complete Specification of the
Subject Application states that the present cancer diagnosis system is able to
detect early cancer, even at early cancer stage 0 or 1, can be detected with
high accuracy. The Paragraph No. [0030] of the Complete Specification is
reproduced hereunder:
“[0030]
(i) The present cancer diagnosis system is able to detect early
cancer. Even early cancer of stage 0 or 1 can be detected with high
accuracy. A specimen, which had been determined to be negative by
an existing tumor marker at the time point of urine collection (2011),
has been tested positive by this test. This 10 patient has developed
cancer during two years in the follow-up observation. That is to say,
cancer undetectable by the existing tumor markers can be detected
by the present invention.
(ii) The presence of many types of cancers can be diagnosed by a
single test. That is, many types of cancers can be diagnosed by a
single medical examination. To date, it 15 has been confirmed that
gastric cancer, colon/rectal cancer, esophageal cancer, pancreatic
cancer, prostate cancer, bile duct cancer, breast cancer, malignant
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
lymphoma, gastrointestinal stromal tumor, cecal cancer, and lung
cancer can be detected by the present cancer diagnosis system.
(iii) The present cancer diagnosis system has high sensitivity. 20 In a
test using 30 specimens, the present cancer diagnosis system has
been able to detect cancers at sensitivity/specificity of 100%.
Moreover, even in a mid-scale test (using 242 specimens), the
present cancer diagnosis system has been able to detect cancers in
cancer patients at a sensitivity of 100% and at a specificity of 95%.”
22.
Based on the above discussion of the Complete Specification, under
the Subject Application, the following can be asserted:
a. Based on the repetition of the analysis to be performed on the
specimen, the outcome / result is highly accurate. As per
Paragraph No. [0030] of the Complete Specification, the present
cancer diagnosis system is able to detect early cancer, even early
cancer stage 0 or 1, and can detect with high accuracy.
b. The invention relates to a method of detecting cancer involving
the steps like collection of data, comparison of the data with
standard values, and that leads to a conclusion based on the result.
23.
Therefore, as per the Complete Specification, the claimed method can
detect cancer, including early-stage cancer, with a high rate of accuracy.
Therefore, the claimed method leads to the detection of cancer.
24.
The Appellant submitted that the detection methods differ
significantly from diagnostic methods. The Paragraph Nos. 51 and 52 of The
Chinese University of Hong Kong (supra) interpret the provision of not to
limit the scope of the word “diagnosis” under the Section 3(i) of the Act to
in vivo cases only. As per the said decision, the in vitro cases should also fall
under the scope of the Section 3(i) of the Act. On the other hand, the
Respondent, relied on Paragraph No. 30 of the said decision, which states
that the absence of the expression “practised on the human or animal body”
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
in Section 3(i) of the Act reinforces the conclusion that the expression
“diagnostic” in Section 3(i) of the Act extends both to in vitro and in vivo
diagnosis.
25.
The Paragraph No. 55 of The Chinese University of Hong Kong
(supra) also states that if the invention in question is incapable of identifying
the existence or non-existence of a disease / disorder condition and further,
testing would be required for such purpose, it would be outside the purview
of Section 3(i) of the Act. The same is also reiterated in Paragraph No. 94 of
Sequenom Inc. & Anr. (supra), wherein the Court held that the patent office
has itself been inconsistent by granting patents for some in vitro
diagnostic-related processes while rejecting others.
26.
The learned Counsel for the Appellant submitted that the detection
methods claimed under the present invention differ significantly from
diagnostic methods. Diagnostic methods require the skill as well as
knowledge of the physician or surgeon to analyze and interpret symptoms,
while in the case of detection, the result is not accompanied by a discussion.
27.
The learned Counsel for the Appellant submitted that detection is
viewed as an independent process directly obtained by the detection method,
which does not require the skill and knowledge of a physician or surgeon.
28.
The learned Counsel for the Appellant further submitted that Claim
No. 5 of the present invention is directed to “a method for identifying an
olfactory receptor in nematodes”, which is a method is for use in deciding
which nematodes to use in the cancer detection method and, therefore, is not
related to the diagnostic method.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
29.
As per the Impugned Order, the object under the present invention
claims a method for detecting and characterizing cancer type in human
subject, which is not allowed under Section 3(i) of the Act.
30.
Under Paragraph Nos. 100 and 101 of the decision in Sequenom Inc.
& Anr. (supra), the Court held that since the extremely accurate test has
98.6% sensitivity and 99.8% specificity, it leads to conformity. It
emphasized that when the language of Section 3(i) of the Act uses the word
diagnostic, it would include both positive and negative diagnoses.
Accordingly, since there is a tangible result achieved by the test which is
being performed, it would defeat the purpose of Section 3(i) of the Act if a
patent is granted. The application cannot be held to be patentable merely
because the test does not confirm the presence of a particular medical
condition. Although it was affirmed that it does eliminate the need for
further examination in respect of that medical condition, it was held that
“While there can be no doubt that the subject invention could be a useful
invention, the mere fact that it is an in vitro method would by itself be
insufficient to make the invention patentable, so long as the purpose of the
process is to diagnose a medical condition.”
31.
The term “diagnostic process” has been explained in Paragraph
No. 79 of Natera Inc. and Anr. (supra), wherein the Court held that the
manner in which the diagnosis is performed would not be patentable. The
Court further observed that with the help of examples that the manner of
checking blood pressure using different tools, the process of checking
glucose levels, the manner of doing a swab test etc., would not be
patentable.
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
32.
In the same way, in the present invention, the method leads to the
identification of cancer with high accuracy. Additionally, the Court in The
Chinese University of Hong Kong (supra), stated that even screening test
would qualify as “diagnostic” for purposes of Section 3(i) of the Act if it
identifies the disease, disorder or condition albeit subject to confirmation by
definitive tests. The relevant paragraph is reproduced hereunder:
“45. Medical literature also makes the distinction between screening
and diagnosis on the basis that diagnostic tests are required to
confirm the results of screening tests. Even in the specific context of
noninvasive prenatal testing (NIPT), reference may be made to the
publication by Medline Plus titled “What is noninvasive prenatal
testing (NIPT) and what disorders it can screen for” and the
publication by the American Clinical Laboratory Association
Screening v. Diagnostic:
Understanding Noninvasive Prenatal Screening”. Adopting this
approach, in my view, is also not in consonance with the meaning of
“diagnostic” in Section 3(i), i.e. capable of uncovering the
pathology. Put differently, if the screening test identifies the disease,
disorder or condition albeit subject to confirmation by definitive
tests, it would still qualify as “diagnostic” for purposes of Section
3(i) because the provision does not use the qualifier “definitive.”
33.
Therefore, based on the discussion of the Complete Specification, it is
inferred that the Complete Specification of the Subject Application provide
that the process sought to be patented is not limited to just a screening
process for diagnosing cancer before it happens, but it also is a general
diagnosing method for cancer. Therefore, the invention claimed in Subject
Application would fall under the Section 3(i) of the Act.
34.
Further, Paragraph No. 50 of The Chinese University of Hong Kong
(supra) also supports the above view. The relevant paragraph is reproduced
hereunder:
“50. The contention of learned counsel for the appellant that
embodiments of the claimed invention should not be reckoned for
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
determination of the claims cannot be accepted. Although the
claims delimit the scope and ambit of the monopoly claim, the
embodiments set out in the complete specification can and should
be examined to assess whether the process is per se diagnostic. In
my view, if the amended claim 1 or current claim 1 is examined in
the context of the above and other paragraphs of the complete
specification, it follows that person(s) skilled in the art would be
able to arrive at a diagnosis as to whether a specific chromosomal
aberration, such as an aneuploidy, exists by adopting this process.
For some understanding of size distribution analysis, reference may
be made to the article “Size based molecular diagnostics using
plasma DNA for noninvasive prenatal testing” by Stephanie C.Y. Yu
et al, dated June 10, 2014, Proceedings of the National Academy of
Sciences, Volume 111, No. 23, pages 8583-8588. If a positive result
for a chromosomal aneuploidy is returned, medical literature
indicates that a medical doctor is likely to opt for definitive
diagnosis by undertaking chorionic villi sampling or amniocentesis.
It is also possible that the claimed invention may be more effective in
identifying certain autosomal aneuploidies and less effective with
chromosomal mutations or sex chromosomal monosomies and
trisomies. On those counts, however, it cannot be concluded that the
process described by the claimed invention is not diagnostic because
neither definitive nor comprehensive diagnosis is a prerequisite to
qualify as diagnostic. Once it is concluded that the claims are patent
ineligible, it is not necessary to deal with the other grounds of
decision, such as lack of inventive step, and sufficient to record that
the impugned order does not warrant interference.”
35.
The Appellant argued that the diagnostic methods require the skill and
knowledge of the physician or surgeon to analyze and interpret symptoms,
while in the case of detection, the result is not accompanied by a discussion.
This Court is of the view that it is immaterial who performs the method. In
such a situation, it would be challenging if this section is kept limited to
only methods practiced by medical practitioners as the application would be
patentable even if the method would be completely autonomous.
36.
Further, the Complete Specification of the Subject Application
provides that the process sought to be patented is not limited to just
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
screening process for diagnosing cancer before it happens; but it also is a
general diagnosing method for cancer. The Appellant’s averment to the
effect that specifications can expand or limit the scope of claims is not
applicable in the present case because there is a contrast between the import
of the specifications versus the import of the amended claims. Even
assuming that the amended claims claim only screening, the claims cannot
be read contrary to specifications. In The Chinese University of Hong Kong
(supra), it was held that to proceed to examine the claims in the context of
the specification, it is necessary to determine whether it specifies a process
for making a diagnosis for treatment. Therefore, the contention of the
Appellant that the determination diagnosing method should be on the basis
of claims and not specification cannot be accepted.
37.
The proposed amended Claim No. 1 read as “…wherein the
determination that the subject has cancer or cancer risk is used as
supporting documentation for a preliminary screening or medical
examination, and not as a definitive medical diagnosis…”. However, the
Complete Specification shows that the screening claimed in amended Claim
No. 1 results in highly accurate results in identification of the cancer.
Therefore, the proposed claims cannot be allowed under Section 3(i) of the
Act.
38.
The proposed amended Claim No. 5 read as “a method for identifying
an olfactory receptor in nematodes for use in the detection method.” Further,
the independent Claim No. 10 claims an in vitro method for identifying
cancer types.
39.
The independent Claim No. 10 would proceed/use the cancer
detection method claimed in Claim Nos. 1 to 4. Therefore, if proposed
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
Claim Nos. 1 to 4 are not acceptable under Section 3(i) of the Act, the
independent Claim No. 10 would also not be acceptable. As regards the
independent Claim No. 5, the Impugned Order rightly held that the said
method is a one of the preparatory steps of the claimed diagnostic method as
mentioned in Claim No. 1, which decides the identification of nematodes
that is to use in the cancer detection method and in isolation, it is of no use.
40.
The Impugned Order rightly noted the steps involved in the Subject
Application while providing reasons for the claimed method to be a
diagnostic method. Accordingly, the Appeal is dismissed and the Impugned
Order dated 29.08.2023 is upheld.
TEJAS KARIA, J
JANUARY 17, 2026
KC / N
Signed By:NEELAM
SHARMA
18:50:22
C.A.(COMM.IPD-PAT) 45/2023
This page is for informational and research purposes only and does not constitute legal advice.
Consult a qualified advocate for advice specific to your situation.
Is your name in this judgment and should it be masked, or is something on this page wrong?
Request a review